An FDA panel convened last week to evaluate the use of laparoscopic power morcellators in removing uterine fibroids, implicated in spreading cancer, failed to reach a consensus on their safety despite outraged testimony from physicians and attendees at the hearing.
An FDA panel convened last week to consider the use of a controversial procedure to remove uterine fibroids failed to come to a clear decision on the cancer risk from laparoscopic power morcellators, despite outraged testimony from dozens of attendees.
Food & Drug Administration (FDA), Johnson & Johnson, Obstetrics and Gynecology Devices Advisory Panel
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/W3nBSJ
Cap comentari:
Publica un comentari a l'entrada